Swiss National Bank Raises Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Swiss National Bank lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 1.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 298,700 shares of the company's stock after buying an additional 4,100 shares during the period. Swiss National Bank owned approximately 0.30% of Neurocrine Biosciences worth $34,416,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of NBIX. Ashton Thomas Private Wealth LLC bought a new stake in shares of Neurocrine Biosciences in the second quarter worth about $28,000. Innealta Capital LLC bought a new stake in shares of Neurocrine Biosciences in the second quarter worth about $30,000. New Covenant Trust Company N.A. bought a new stake in shares of Neurocrine Biosciences in the first quarter worth about $32,000. EdgeRock Capital LLC bought a new stake in shares of Neurocrine Biosciences in the second quarter worth about $35,000. Finally, Blue Trust Inc. grew its stake in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after purchasing an additional 220 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Wall Street Analyst Weigh In

NBIX has been the topic of several research reports. Guggenheim lifted their price objective on Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. Piper Sandler raised Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $131.00 to $159.00 in a research report on Thursday, August 29th. Raymond James reaffirmed an "outperform" rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. StockNews.com cut Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 1st. Finally, Royal Bank of Canada cut their price objective on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a research report on Friday, October 4th. Five research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences currently has an average rating of "Moderate Buy" and an average price target of $163.91.

Neurocrine Biosciences Stock Performance

NASDAQ:NBIX opened at $123.29 on Thursday. The stock has a market capitalization of $12.48 billion, a P/E ratio of 33.05 and a beta of 0.35. The company has a 50 day moving average price of $118.44 and a 200 day moving average price of $132.24. Neurocrine Biosciences, Inc. has a fifty-two week low of $108.63 and a fifty-two week high of $157.98.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.